Inci Alacacioglu
Overview
Explore the profile of Inci Alacacioglu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Ayhan Z, Yildirim Karabag R, Alacacioglu I, Kaynak S, Kocak N
Turk J Ophthalmol
. 2017 Apr;
47(2):110-112.
PMID: 28405486
Bilateral non-granulomatous anterior uveitis with left vitritis and macular edema were detected in a 19-year-old woman presenting with blurred vision in her left eye. Light microscopic study of the pathologic...
22.
Piskin O, Ozsan G, Ates H, Ozcan M, Demirkan F, Alacacioglu I, et al.
Turk J Haematol
. 2016 Jun;
23(3):136-41.
PMID: 27265480
It has been shown that imatinib mesylate, a drug used in the treatment of chronic myelogenous leukemia, inhibits the effect of stem cell factor, which has a central role in...
23.
Ozcan M, Piskin O, Alacacioglu I, Undar B
Turk J Haematol
. 2016 Jun;
23(2):119.
PMID: 27265295
t(1;3)(p36;p21) is a recurrent reciprocal translocation found in a subset of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) characterized by trilineage dysplasia, especially dysmegakaryopoiesis and poor prognosis. In the literature, some...
24.
Ozcan M, Akarsu M, Demirkan F, Akpinar H, Yuksel F, Ozsan G, et al.
Turk J Haematol
. 2016 Jun;
23(2):94-9.
PMID: 27265290
Background: The clinical course of patients with inflammatory bowel disease (IBD) is frequently complicated by thromboembolic events and may involve the arterial and venous systems. Although not uniformly documented, several...
25.
Ozcan M, Piskin O, Alacacioglu I, Savran Y, Ozsan H
Turk J Haematol
. 2016 Jun;
21(1):49.
PMID: 27263648
No abstract available.
26.
Piskin O, Ozcan M, Ozcan G, Ates H, Demirkan F, Alacacioglu I, et al.
Turk J Haematol
. 2016 Jun;
24(1):23-7.
PMID: 27263481
Fludarabine-containing combinations have additive cell killing against leukemic blasts in vitro. It has also been shown that imatinib mesylate combined with fludarabine or cladribine had an additive effect on CML...
27.
Calli A, Morgul Y, Alacacioglu I, Bener S, Payzin B
Turk J Haematol
. 2016 Mar;
30(2):198-203.
PMID: 26923635
Langerhans cell sarcoma is a rare, high-grade neoplasm with overtly malignant cytological features and the Langerhans phenotype. Herein, we present a rare case of Langerhans cell sarcoma in a 65-year-old...
28.
Ozdemirkiran F, Payzin B, Kiper H, Kabukcu S, Akgun Cagliyan G, Kahraman S, et al.
Turk J Haematol
. 2015 Apr;
32(4):323-8.
PMID: 25914025
Objective: Immune thrombocytopenia (ITP) is an immune-mediated disease characterized by transient or persistent decrease of the platelet count to less than 100x109/L. Although it is included in a benign disease...
29.
Alacacioglu I, Medeni S, Ozsan G, Payzin B, Gokmen Sevindik O, Acar C, et al.
Chemotherapy
. 2015 Apr;
60(4):219-23.
PMID: 25871894
Multiple induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). However, there have been no prospective randomized trials that directly compare these regimens. In this study,...
30.
Sevindik O, Mersin S, Katgi A, Tunali S, Solmaz S, Acar C, et al.
Clin Lymphoma Myeloma Leuk
. 2015 Mar;
15(6):e101-4.
PMID: 25790738
Introduction: Essential thrombocythemia (ET) is the most common of the myeloproliferative neoplasms. For better predicting the occurrence of thrombotic events, an International Prognostic Score of Thrombosis for ET (IPSET-Thrombosis) was...